Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost

Gregory Katz, Clark Springs, E. Randy Craven, Michela Montecchi-Palmer

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: The preservative benzalkonium chloride (BAK) may adversely affect ocular surface health. This study evaluated symptoms of ocular surface disease (OSD) in patients previously treated with a BAK-preserved therapy to lower their intraocular pressure, who either continued that therapy or switched to a BAK-free therapy. Methods: Eligible adult patients with ocular hypertension or open-angle glaucoma that had been controlled with BAK-preserved latanoprost 0.005% monotherapy (Xalatan®) for at least one month and had a score of ≥ 13 (0 = none, 100 = most severe) on the Ocular Surface Disease Index (OSDI) questionnaire were entered into this prospective, double-masked, randomized, active-controlled, multicenter trial. By random assignment, patients either continued with BAK-preserved latanoprost 0.005% or transitioned to BAK-free travoprost 0.004% (Travatan Z® ophthalmic solution). OSDI scores were assessed again after six and 12 weeks. Results: For the 678 evaluable patients, mean change in OSDI score from baseline to week 12 favored the travoprost 0.004% BAK-free group, but was not statistically different between groups (P = 0.10). When patients with mild OSD at baseline were assessed after 12 weeks, the mean OSDI score was significantly lower (P = 0.04) in the BAK-free travoprost 0.004% group (score = 11.6 ± 10.8 units) than in the BAK-preserved latanoprost 0.005% group (score = 14.4 ± 11.9 units), and a significantly larger percentage (P > 0.01) improved to normal OSDI scores in the BAK-free travoprost 0.004% group (62.9% of group) than in the BAKpreserved latanoprost 0.005% group (47.0% of group). Patients pretreated with BAK-preserved latanoprost 0.005% for > 24 months were significantly more likely (P = 0.03) to improve to a normal OSDI score after 12 weeks if they were switched to BAK-free travoprost 0.004% (47.9% of group) than if they remained on BAK-preserved latanoprost 0.005% (33.9% of group). Conclusions: Switching from BAK-preserved latanoprost 0.005% to BAK-free travoprost 0.004% yielded significant improvements in symptoms of OSD in patients with glaucoma or ocular hypertension.

Original languageEnglish
Pages (from-to)1253-1261
Number of pages9
JournalClinical Ophthalmology
Volume4
Issue number1
DOIs
StatePublished - 2010

Fingerprint

latanoprost
Benzalkonium Compounds
Ocular Hypertension
Eye Diseases
Glaucoma
Travoprost

Keywords

  • Benzalkonium chloride
  • Glaucoma
  • Ocular surface
  • Preservative
  • Prostaglandin analog

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. / Katz, Gregory; Springs, Clark; Craven, E. Randy; Montecchi-Palmer, Michela.

In: Clinical Ophthalmology, Vol. 4, No. 1, 2010, p. 1253-1261.

Research output: Contribution to journalArticle

Katz, Gregory ; Springs, Clark ; Craven, E. Randy ; Montecchi-Palmer, Michela. / Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. In: Clinical Ophthalmology. 2010 ; Vol. 4, No. 1. pp. 1253-1261.
@article{813190e4f1fa49d2959c316c85dcedc3,
title = "Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost",
abstract = "Purpose: The preservative benzalkonium chloride (BAK) may adversely affect ocular surface health. This study evaluated symptoms of ocular surface disease (OSD) in patients previously treated with a BAK-preserved therapy to lower their intraocular pressure, who either continued that therapy or switched to a BAK-free therapy. Methods: Eligible adult patients with ocular hypertension or open-angle glaucoma that had been controlled with BAK-preserved latanoprost 0.005{\%} monotherapy (Xalatan{\circledR}) for at least one month and had a score of ≥ 13 (0 = none, 100 = most severe) on the Ocular Surface Disease Index (OSDI) questionnaire were entered into this prospective, double-masked, randomized, active-controlled, multicenter trial. By random assignment, patients either continued with BAK-preserved latanoprost 0.005{\%} or transitioned to BAK-free travoprost 0.004{\%} (Travatan Z{\circledR} ophthalmic solution). OSDI scores were assessed again after six and 12 weeks. Results: For the 678 evaluable patients, mean change in OSDI score from baseline to week 12 favored the travoprost 0.004{\%} BAK-free group, but was not statistically different between groups (P = 0.10). When patients with mild OSD at baseline were assessed after 12 weeks, the mean OSDI score was significantly lower (P = 0.04) in the BAK-free travoprost 0.004{\%} group (score = 11.6 ± 10.8 units) than in the BAK-preserved latanoprost 0.005{\%} group (score = 14.4 ± 11.9 units), and a significantly larger percentage (P > 0.01) improved to normal OSDI scores in the BAK-free travoprost 0.004{\%} group (62.9{\%} of group) than in the BAKpreserved latanoprost 0.005{\%} group (47.0{\%} of group). Patients pretreated with BAK-preserved latanoprost 0.005{\%} for > 24 months were significantly more likely (P = 0.03) to improve to a normal OSDI score after 12 weeks if they were switched to BAK-free travoprost 0.004{\%} (47.9{\%} of group) than if they remained on BAK-preserved latanoprost 0.005{\%} (33.9{\%} of group). Conclusions: Switching from BAK-preserved latanoprost 0.005{\%} to BAK-free travoprost 0.004{\%} yielded significant improvements in symptoms of OSD in patients with glaucoma or ocular hypertension.",
keywords = "Benzalkonium chloride, Glaucoma, Ocular surface, Preservative, Prostaglandin analog",
author = "Gregory Katz and Clark Springs and Craven, {E. Randy} and Michela Montecchi-Palmer",
year = "2010",
doi = "10.2147/OPTH.S14113",
language = "English",
volume = "4",
pages = "1253--1261",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost

AU - Katz, Gregory

AU - Springs, Clark

AU - Craven, E. Randy

AU - Montecchi-Palmer, Michela

PY - 2010

Y1 - 2010

N2 - Purpose: The preservative benzalkonium chloride (BAK) may adversely affect ocular surface health. This study evaluated symptoms of ocular surface disease (OSD) in patients previously treated with a BAK-preserved therapy to lower their intraocular pressure, who either continued that therapy or switched to a BAK-free therapy. Methods: Eligible adult patients with ocular hypertension or open-angle glaucoma that had been controlled with BAK-preserved latanoprost 0.005% monotherapy (Xalatan®) for at least one month and had a score of ≥ 13 (0 = none, 100 = most severe) on the Ocular Surface Disease Index (OSDI) questionnaire were entered into this prospective, double-masked, randomized, active-controlled, multicenter trial. By random assignment, patients either continued with BAK-preserved latanoprost 0.005% or transitioned to BAK-free travoprost 0.004% (Travatan Z® ophthalmic solution). OSDI scores were assessed again after six and 12 weeks. Results: For the 678 evaluable patients, mean change in OSDI score from baseline to week 12 favored the travoprost 0.004% BAK-free group, but was not statistically different between groups (P = 0.10). When patients with mild OSD at baseline were assessed after 12 weeks, the mean OSDI score was significantly lower (P = 0.04) in the BAK-free travoprost 0.004% group (score = 11.6 ± 10.8 units) than in the BAK-preserved latanoprost 0.005% group (score = 14.4 ± 11.9 units), and a significantly larger percentage (P > 0.01) improved to normal OSDI scores in the BAK-free travoprost 0.004% group (62.9% of group) than in the BAKpreserved latanoprost 0.005% group (47.0% of group). Patients pretreated with BAK-preserved latanoprost 0.005% for > 24 months were significantly more likely (P = 0.03) to improve to a normal OSDI score after 12 weeks if they were switched to BAK-free travoprost 0.004% (47.9% of group) than if they remained on BAK-preserved latanoprost 0.005% (33.9% of group). Conclusions: Switching from BAK-preserved latanoprost 0.005% to BAK-free travoprost 0.004% yielded significant improvements in symptoms of OSD in patients with glaucoma or ocular hypertension.

AB - Purpose: The preservative benzalkonium chloride (BAK) may adversely affect ocular surface health. This study evaluated symptoms of ocular surface disease (OSD) in patients previously treated with a BAK-preserved therapy to lower their intraocular pressure, who either continued that therapy or switched to a BAK-free therapy. Methods: Eligible adult patients with ocular hypertension or open-angle glaucoma that had been controlled with BAK-preserved latanoprost 0.005% monotherapy (Xalatan®) for at least one month and had a score of ≥ 13 (0 = none, 100 = most severe) on the Ocular Surface Disease Index (OSDI) questionnaire were entered into this prospective, double-masked, randomized, active-controlled, multicenter trial. By random assignment, patients either continued with BAK-preserved latanoprost 0.005% or transitioned to BAK-free travoprost 0.004% (Travatan Z® ophthalmic solution). OSDI scores were assessed again after six and 12 weeks. Results: For the 678 evaluable patients, mean change in OSDI score from baseline to week 12 favored the travoprost 0.004% BAK-free group, but was not statistically different between groups (P = 0.10). When patients with mild OSD at baseline were assessed after 12 weeks, the mean OSDI score was significantly lower (P = 0.04) in the BAK-free travoprost 0.004% group (score = 11.6 ± 10.8 units) than in the BAK-preserved latanoprost 0.005% group (score = 14.4 ± 11.9 units), and a significantly larger percentage (P > 0.01) improved to normal OSDI scores in the BAK-free travoprost 0.004% group (62.9% of group) than in the BAKpreserved latanoprost 0.005% group (47.0% of group). Patients pretreated with BAK-preserved latanoprost 0.005% for > 24 months were significantly more likely (P = 0.03) to improve to a normal OSDI score after 12 weeks if they were switched to BAK-free travoprost 0.004% (47.9% of group) than if they remained on BAK-preserved latanoprost 0.005% (33.9% of group). Conclusions: Switching from BAK-preserved latanoprost 0.005% to BAK-free travoprost 0.004% yielded significant improvements in symptoms of OSD in patients with glaucoma or ocular hypertension.

KW - Benzalkonium chloride

KW - Glaucoma

KW - Ocular surface

KW - Preservative

KW - Prostaglandin analog

UR - http://www.scopus.com/inward/record.url?scp=78650682979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650682979&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S14113

DO - 10.2147/OPTH.S14113

M3 - Article

C2 - 21151330

AN - SCOPUS:78650682979

VL - 4

SP - 1253

EP - 1261

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

IS - 1

ER -